1-4 of 4
Authors: Gregory Johnson
Save search
Sort by
Journal Article

CTNI-26. PHASE 2 STUDY OF DIANHYDROGALACTITOL (VAL-083) IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE GLIOBLASTOMA IN THE RECURRENT AND ADJUVANT SETTING

PDF
Barbara O'Brien and others
Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Page vi65, https://doi.org/10.1093/neuonc/noab196.251
Published: 12 November 2021
Journal Article

CTNI-21. PHASE 2 STUDY OF VAL-083 AND RADIOTHERAPY IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM

PDF
Zhong-ping Chen and others
Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Pages vi63–vi64, https://doi.org/10.1093/neuonc/noab196.246
Published: 12 November 2021
Journal Article

ACTR-12. PHASE 2 STUDY OF DIANHYDROGALACTITOL (VAL-083) IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE GLIOBLASTOMA IN THE RECURRENT AND ADJUVANT SETTING

PDF
Barbara O’Brien and others
Neuro-Oncology, Volume 21, Issue Supplement_6, November 2019, Pages vi14–vi15, https://doi.org/10.1093/neuonc/noz175.055
Published: 11 November 2019
Journal Article

ACTR-06. CLINICAL TRIAL OF VAL-083 IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM: HALF-WAY REPORT

PDF
Zhong-ping Chen and others
Neuro-Oncology, Volume 21, Issue Supplement_6, November 2019, Page vi13, https://doi.org/10.1093/neuonc/noz175.050
Published: 11 November 2019